IP Library Granted Patent US 8,447,395
Granted Patent B2
US 8,447,395 · App. 12/958,623 · Granted May 21, 2013

Treating bacteria with electric fields

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,447,395
App. No.
12/958,623
Granted
May 21, 2013
Kind
B2
Abstract

Cells that are in the process division are vulnerable to damage by AC electric fields that have specific frequency and field strength characteristics. The selective destruction of rapidly dividing cells can therefore be accomplished by imposing an AC electric field in a target region for extended periods of time at particular frequencies with particular filed strengths. Some of the cells that divide while the field is applied will be damaged, but the cells that do not divide will not be harmed. This selectively damages rapidly dividing cells like bacteria, but does not harm normal cells that are not dividing. Since the vulnerability of the dividing cells is strongly related to the alignment between the long axis of the dividing cells and the lines of force of the electric field, improved results can be obtained when the field is sequentially imposed in different directions.

Claims (14)

1. An apparatus for selectively destroying or inhibiting the growth of bacteria located within a target region of a patient, the apparatus comprising:

a first pair of insulated electrodes, wherein each of the electrodes has surface configured to facilitate capacitive coupling of an electric field into the patient's body; and

an AC voltage source operatively connected to the electrodes;

wherein the AX voltage source and the electrodes are configured so that, when the electrodes are placed against the patient's body and the AC voltage source is activated, an AC electric field is capacitively coupled into the target region of the patient via the electrodes,

wherein the frequency of the electric field is between 5 MHz and 20 MHz, wherein the strength of the electric field in at least a portion of the target region is between 2 V/cm and 100V/cm, wherein the imposed electric field has frequency characteristics that correspond to a vulnerability of the bacteria, wherein the electric field is strong enough to damage, during cell division, a significant portion of the bacteria whose long axis is generally aligned with the lines of force of the electric field, and wherein the electric field leaves non-dividing cells located within the target region substantially unharmed.

2. The apparatus of claim 1 , wherein the strength of the electric field in at least a portion of the target region is between 5 V/cm and 20 V/cm.

3. The apparatus of claim 1 , wherein the strength of the electric field in at least a portion of the target region is between 10 V/cm and 17 V/cm.

4. The apparatus of claim 1 , wherein the frequency of the electric field is about 10 MHz.

5. The apparatus of claim 1 , wherein the surface of each of the electrodes is insulated from the AC voltage source by a thin dielectric coating that has a very high dielectric constant.

6. The apparatus of claim 1 , further comprising:

a second pair of insulated electrodes, each having a surface configured to facilitate capacitively coupling of an electric field into the patient's body; and

a switching mechanism that alternately applies the output of the AC voltage source to either (a) the first pair of electrodes or (b) the second pair of electrodes.

7. The apparatus of claim 6 , wherein the first pair of electrodes is oriented with respect to the second pair of electrodes so that the field that is coupled into the patient when the AC voltage is applied to the first pair of electrodes is roughly perpendicular to the field that is coupled into the patient when the AC voltage is applied to the second pair of electrodes.

8. The apparatus of claim 6 , wherein the surface of each of the electrodes is insulated from the AC voltage source by a thin dielectric coating that has a very high dielectric constant.

Assignments (17)
PATENT SECURITY AGREEMENT Recorded May 4, 2024
From: NOVOCURE GMBH (SWITZERLAND)
To: BIOPHARMA CREDIT PLC
Reel/Frame 067315/0399 →
RELEASE OF SECURITY INTEREST Recorded Apr 24, 2024
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NOVOCURE GMBH
Reel/Frame 067211/0839 →
SECURITY INTEREST Recorded Nov 6, 2020
From: NOVOCURE GMBH
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 054344/0510 →
RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 45278 0825 Recorded Aug 25, 2020
From: BIOPHARMA CREDIT PLC
To: NOVOCURE LIMITED
Reel/Frame 053597/0335 →
RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 50395/0398 Recorded Aug 19, 2020
From: BPCR LIMITED PARTNERSHIP
To: NOVOCURE GMBH
Reel/Frame 053538/0623 →
OMNIBUS CONFIRMATION OF ASSIGNMENT AGREEMENT Recorded May 21, 2020
From: BIOPHARMA CREDIT PLC
To: BPCR LIMITED PARTNERSHIP
Reel/Frame 052741/0173 →
RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 045278/0825 Recorded Apr 14, 2020
From: BIOPHARMA CREDIT PLC
To: NOVOCURE LIMITED
Reel/Frame 052391/0549 →
RELEASE OF SECURITY INTEREST Recorded Apr 13, 2020
From: BIOPHARMA CREDIT PLC
To: NOVOCURE LIMITED
Reel/Frame 052383/0705 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2019
From: NOVOCURE LIMITED
To: NOVOCURE GMBH
Reel/Frame 050110/0098 →
SECURITY INTEREST Recorded May 6, 2019
From: NOVOCURE GMBH
To: BIOPHARMA CREDIT PLC
Reel/Frame 050395/0398 →
SECURITY INTEREST Recorded Feb 7, 2018
From: NOVOCURE LIMITED
To: BIOPHARMA CREDIT PLC
Reel/Frame 045278/0825 →
SECURITY INTEREST Recorded Feb 7, 2018
From: NOVOCURE LIMITED
To: BIOPHARMA CREDIT PLC
Reel/Frame 045284/0851 →
RELEASE OF SECURITY INTEREST Recorded Feb 7, 2018
From: BIOPHARMA SECURED INVESTMENTS III HOLDINGS CAYMAN LP
To: NOVOCURE LIMITED
Reel/Frame 044858/0416 →
SECURITY INTEREST Recorded Feb 2, 2015
From: NOVOCURE LIMITED
To: BIOPHARMA SECURED INVESTMENTS III HOLDINGS CAYMAN LP
Reel/Frame 034866/0402 →
CHANGE OF NAME Recorded Jan 23, 2015
From: STANDEN LIMITED
To: NOVOCURE LIMITED
Reel/Frame 034795/0933 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S NAME AND ADDRESS TO: STANDEN LIMITED; LE MASURIER HOUSE, LA RUE LE MASURIER, ST. HELIER, JERSEY JE24YE PREVIOUSLY RECORDED ON REEL 025833 FRAME 0436. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNORS RIGHT, TITLE, AND INTEREST. Recorded Jan 18, 2015
From: PALTI, YORAM; GILADI, MOSHE
To: STANDEN LIMITED
Reel/Frame 034780/0892 →
RELEASE OF SECURITY INTEREST Recorded Dec 20, 2013
From: DEUTSCHE BANK TRUST COMPANY AMERICAS
To: NOVOCURE LIMITED
Reel/Frame 031866/0567 →